Extragonadal
androgens play a pivotal role in
prostate cancer disease progression on
androgen receptor signaling inhibitors (ARSi), including
abiraterone and
enzalutamide. We aimed to investigate if germline variants in genes involved in extragonadal
androgen synthesis contribute to resistance to ARSi and may predict clinical outcomes on ARSi. We included ARSi naive metastatic
prostate cancer patients treated with
abiraterone or
enzalutamide and determined 18 germline variants in six genes involved in extragonadal
androgen synthesis. Variants were tested in univariate and multivariable analysis for the relation with overall survival (OS) and time to progression (
TTP) by Cox regression, and PSA response by logistic regression. A total of 275 patients were included. From the investigated genes CYP17A1, HSD3B1,
CYP11B1, AKR1C3, SRD5A1 and SRD5A2, only rs4736349 in
CYP11B1 in homozygous form (TT), present in 54 patients (20%), was related with a significantly worse OS (HR = 1.71, 95% CI 1.09 - 2.68, p = 0.019) and
TTP (HR = 1.50, 95% CI 1.08 - 2.09, p = 0.016), and was related with a significantly less frequent PSA response (OR = 0.48, 95% CI 0.24 - 0.96, p = 0.038) on
abiraterone or
enzalutamide in a multivariable analysis. The frequent germline variant rs4736349 in
CYP11B1 is, as homozygote, an independent negative prognostic factor for treatment with
abiraterone or
enzalutamide in ARSi naive metastatic
prostate cancer patients. Our findings warrant prospective investigation of this potentially important predictive
biomarker.